Truist analyst Richard Newitter lowered the firm’s price target on Inspire Medical (INSP) to $50 from $64 and keeps a Hold rating on the shares. The company has significantly cut FY26 guidance despite a modest Q1 revenue and EPS beat as I5 coding and WISeR impacts were worse than expected, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $54 from $67 at JPMorgan
- Inspire Medical price target lowered to $55 from $62 at Evercore ISI
- Inspire Medical price target lowered to $45 from $56 at RBC Capital
- Inspire Medical price target lowered to $55 from $70 at Mizuho
- Inspire Medical price target lowered to $65 from $70 at Stifel